Physician profile
Frederick Banerman
NPI 1194703140
$3,882.25
in general payments reported to CMS, 2019-2025
27 companies · $985 in 2025
The $985 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $556 · 2023: $456 · 2024: $1,114 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.41 | 2021-2025 | Wainua, Farxiga, Evusheld |
| Amgen INC. | $363.09 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $335.63 | 2023-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $326.23 | 2021-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $271.41 | 2023-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.68 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $239.88 | 2023-2025 | Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $227.75 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $165.57 | 2021-2025 | |
| Boston Scientific Corporation | $148.53 | 2021 | |
| Scpharmaceuticals INC. | $140.27 | 2024-2025 | |
| Edwards Lifesciences Corporation | $135.02 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.94 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $115.25 | 2022-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $105.71 | 2024-2025 | Barostim Neo System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.79 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $85.50 | 2023 | Evkeeza |
| Abbott Laboratories | $76.05 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Atricure, INC. | $69.96 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Merck Sharp & Dohme LLC | $63.01 | 2021-2024 | Verquvo |
| Abiomed | $45.34 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $33.11 | 2024 | |
| Lilly USA, LLC | $19.61 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.50 | 2024 | Edarbi |
| Daiichi Sankyo INC. | $17.00 | 2023 | Injectafer |
| Altathera Pharmaceuticals LLC | $16.33 | 2022 | |
| United Therapeutics Corporation | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Banerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.